International Psoriasis Council

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

Commentary: Sex differences in immune responses that underlie COVID-19 disease outcomes

computer with words expert commentary

Errol Prens, MD, PhD
Erasmus University Medical Center
Rotterdam, Netherlands
IPC Councilor

PUBLICATION

Sex differences in immune responses that underlie COVID-19 disease outcomes. Takahashi T, Ellingson MK, Wong P, Israelow B, Lucas C, Klein J, Silva J, Mao T, Oh JE, Tokuyama M, Lu P, Venkataraman A, Park A, Liu F, Meir A, Sun J, Wang EY, Casanovas-Massana A, Wyllie AL, Vogels CBF, Earnest R, Lapidus S, Ott IM, Moore AJ; Yale IMPACT Research Team, Shaw A, Fournier JB, Odio CD, Farhadian S, Dela Cruz C, Grubaugh ND, Schulz WL, Ring AM, Ko AI, Omer SB, Iwasaki A. Nature. 2020 Dec;588(7837):315-320. doi: 10.1038/s41586-020-2700-3. Epub 2020 Aug 26. PMID: 32846427; PMCID: PMC7725931.

COMMENTARY

Because of the growing body of evidence indicating sex differences in the clinical outcomes of coronavirus disease 2019 (COVID-19) infection, the IMPACT Research Team from Yale University investigated sex differences in viral loads, SARS-CoV-2-specific antibody titers, plasma cytokines, as well as blood cell phenotyping in COVID-19 patients. They discovered essential differences in immune responses during the disease course of SARS-CoV-2 infection in male versus female patients. First, they found that the levels of important pro-inflammatory innate immune chemokines and cytokines such as IL-8, IL-18 (at baseline), and CCL5 (longitudinal analysis) were higher in male patients, which correlated with more elevated non-classical monocytes (at baseline) and more severe disease. Second, they observed a more robust T cell response among female patients than male patients at baseline. Collectively, their data suggest that vaccines and therapies to elevate T cell immune response to SARS-CoV-2 might be warranted for male patients. In contrast, female patients might benefit from therapies that dampen innate immune activation early during disease. The immune landscape in COVID-19 patients is considerably different between the sexes. They conclude that these differences may underlie heightened disease susceptibility in men.

The authors recognize an important limitation of their study: healthy healthcare workers who served as controls were not matched to patients based on age, BMI, or underlying risk factors. Despite their corrections for those confounders in their statistical analyses, residual confounding is not ruled out due to underlying risk factors not available for the healthcare workers’ controls. The limited sample size of this study is an explicit limitation.

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Categories

Tags

Recent Posts

PASI 90 blog post with Dr. Maskin

Access to Biologics in Argentina: Rethinking Time to PASI 90

Blog Post - Psoriasis Hub

IPC Partners with Scientific Education Support to Create New Psoriasis and Psoriatic Arthritis Hub

Blog -Expert Insights-Erica-Alba (1)

Monkeypox Symptoms, Treatment, Prevention, and Impact on Psoriasis Patients

Also Read

Filip Rob Commentary graphic
deucravacitinib

Commentary: Deucravacitinib Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Efficacy and Safety Results from the 52-week, Randomized, Double-blinded, Placebo-controlled Phase 3 POETYK PSO-1 Trial

The United States Food and Drug Administration (FDA) has approved deucravacitinib to treat psoriasis. Recently, 52-week efficacy and safety data of deucravacitinib were compared and contrasted with placebo and apremilast. The outcome of this comparative study lends support for the position of deucravacitinib in the spectrum of treatments for psoriasis.

Read More
Blog - Commentary - Alexander Egeberg - graphic
Secukinumab

Commentary: Drug Survival Associated with Effectiveness and Safety of Treatment with Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients with Psoriasis

Real-world evidence studies become crucial to achieving the evidence needed in clinical practice. But how are data evaluated in the complexity of the real world? Alexander Egeberg, MD, PhD, DMSc, discusses a present study that examined drug survival among 16,122 treatment courses of biologic therapy with either guselkumab, ixekizumab, secukinumab, ustekinumab, or adalimumab, using United Kingdom registry data.

Read More

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.